| New York | |
| London | |
| Hong Kong | |
| Tokyo | |
| Sydney |

The world's largest biotechnology company, Amgen Inc, recently announced that it would pay over $1 billion to buy Micromet Inc (MITI.O), which has several cancer drugs in development.
Amgen plans to pay $11 per share in cash for Micromet, which is a premium of nearly 33 percent to the smaller firm's closing price on January 25. In July, the two companies had already signed a drug development deal.
The pipeline of Micromet includes a treatment in mid-stage development for acute lymphoblastic leukemia.
Amgen is being advised by Moelis & Company LLC and Sullivan & Cromwell LLP. Goldman, Sachs & Co. and Cooley LLP are offering financial and legal advice, respectively, to Micromet.
On Tuesday, U.S. stock index futures pointed to a higher open on Wall Street. The surge may halt a four-session losing...
On Tuesday, German government bond yields hit their lowest level since September and European shares fell sharply. This as...
A leading online Forex Broker, UFX Bank, is producing a weekly forex market outlook video that will feature industry expert...
A leading provider of online forex trading, UFX Bank, has chosen Divisa Capital, LP for offering tier 1 liquidity available...
UFX Bank has expanded its platform by including Binary Options Trading to open up the world of financial trade to a wider...
UFX Bank, a leading online forex broker, has recently announced the launch of a new forex pair Oil/USD, which will allow...
Micromet is surely a good
Micromet is surely a good prospect for Agmen, worthwhile acquisition.